BRAF and amyotrophic lateral sclerosis: For instance, patients with melanoma and BRAF gene mutations have significantly improved rates of overall and progression-free survival when treated with a BRAF kinase inhibitor.4 It seems that therapeutic strategies for ALS are also moving toward precision medicine and groundbreaking targeted trials for SOD1-related ALS have already been undertaken or are underway with antisense oligonucleotides,5 arimoclomol (ClinicalTrials.gov NCT00706147), and pyrimethamine.6